This study will evaluate the initial safety and effectiveness of an investigational drug,
MLN8237, added to routine radiation therapy and cetuximab in patients with head and neck
cancer. This study will also determine the highest dose of MLN8237 that can be given together
with cetuximab and radiation therapy without causing severe side effects.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania